DrugPatentWatch Database Preview
LICART Drug Profile
» See Plans and Pricing
When do Licart patents expire, and when can generic versions of Licart launch?
Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA.
The generic ingredient in LICART is diclofenac epolamine. There are forty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the diclofenac epolamine profile page.
Summary for LICART
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LICART at DailyMed |
Generic Entry Opportunity Date for LICART
Generic Entry Date for LICART*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
SYSTEM;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for LICART
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibsa Inst Bio | LICART | diclofenac epolamine | SYSTEM;TOPICAL | 206976-001 | Dec 19, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
